Tissue Diagnostics Market worth $14.02 billion by 2030, growing at a CAGR of 7.74% - Exclusive Report by 360iResearch

The Global Tissue Diagnostics Market to grow from USD 7.71 billion in 2022 to USD 14.02 billion by 2030, at a CAGR of 7.74%.



Tissue Diagnostics Market - Exclusive Report by 360iResearch

PUNE, MAHARASHTRA, INDIA, November 9, 2023 /EINPresswire.com/ -- The "Tissue Diagnostics Market by Product (Accessories, Consumables, Instruments), Technology (Digital Pathology & Workflow, Immunohistochemistry, In Situ Hybridization), Indications, End-User - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Tissue Diagnostics Market to grow from USD 7.71 billion in 2022 to USD 14.02 billion by 2030, at a CAGR of 7.74%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/tissue-diagnostics?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Tissue diagnostics is a medical field that involves examining and analyzing tissue samples from a patient's body to diagnose diseases or conditions. It is crucial in diagnosing and treating various medical conditions, including cancer and other tissue-related diseases. Tissue diagnostics has applications across several clinical areas and is crucial in personalized medicine for assisting in early disease detection. An increase in global cancer prevalence rates and an aging population drive the demand for tissue diagnostic services. Advancements in genomics have led to the identification of numerous biomarkers associated with diseases, which have further spurred the need for accurate diagnostic tests. However, high costs associated with diagnostic instruments and services might impede their adoption by small-scale healthcare providers or low-resource settings. The lack of skilled professionals capable of interpreting complex test results and

insufficient pathologists worldwide could hinder market expansion. Technological advances such as artificial intelligence (AI) integration with digital pathology have opened up new opportunities for the market players. AI-based algorithms can aid pathologists in detecting subtle morphological changes within tissues that may be easily overlooked. Additionally, growing investments from governments and private organizations towards healthcare infrastructure are expected to provide more avenues for growth in this sector.

Indications: Exponential use of tissue diagnostics in the detection and characterization of numerous cancer types

Tissue diagnostics play a pivotal role in the early detection and characterization of breast cancer, allowing personalized therapies to improve patient outcomes. Techniques such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are widely used to identify hormone receptor status, guiding targeted therapy decisions. Identifying different subtypes of gastric cancer using tissue diagnostics assists clinicians with prognosis prediction and therapy selection. IHC is commonly employed to detect molecular biomarkers such as HER2 overexpression that directs the use of targeted therapies such as trastuzumab. Accurate diagnosis and subtyping of lymphoma are crucial for appropriate treatment planning since it comprises a heterogeneous group of malignancies involving immune system cells. Tissue diagnostic techniques can identify specific cell markers to differentiate between Hodgkin's and non-Hodgkin's lymphomas or even identify subtypes within these categories. Tissue diagnostics helps identify genetic alterations such as EGFR mutations, ALK rearrangements, and PD-L1 expression levels that can guide treatment decisions. Prostate cancer is the second most common cancer among men globally. Tissue diagnostics are crucial for determining the pathological grade of tumors through Gleason scoring and evaluating prognostic markers such as Ki-67 and PTEN loss.

End-User: Significant utilization of tissue diagnostics in clinical pathology laboratories to improve patient care quality

The primary need for tissue diagnostics in clinical pathology laboratories is to detect and diagnose various diseases at the molecular level. It helps pathologists identify biomarkers associated with specific diseases using techniques such as immunohistochemistry (IHC), in situ hybridization (ISH), and hematoxylin (H&E) staining. Contract research organizations (CROs) require tissue diagnostics services for preclinical and clinical research studies for pharmaceutical companies and biotechnology firms. These organizations prioritize cost-effectiveness, scalability, and turnaround times in choosing tissue diagnostic solutions. Tissue diagnostics are critical for patient diagnosis, treatment selection, and disease monitoring in hospital settings. Hospitals require reliable diagnostic solutions that provide accurate results with a minimal turnaround time to improve patient care quality while minimizing costs. Pharmaceutical companies utilize tissue diagnostics for drug development and clinical trials, necessitating solutions that identify target populations for precision medicine, optimize patient stratification, and evaluate treatment response in real-time. Academic and research institutions require cutting-edge tissue diagnostic solutions to investigate disease mechanisms, discover novel biomarkers, and advance therapeutic development. These laboratories prefer innovative technologies supporting high-

throughput analysis and multiplexing capabilities.

Technology: Adoption of digital pathology technology for the management of digitized histological samples through computer technology
Digital pathology uses computer technology to manage information generated from digitized histological samples. Digital pathology systems enable efficient diagnosis, interpretation, image analysis, storage, and sharing of digital slides. The increased accuracy and reduced turnaround time make it an essential tool for pathologists worldwide. Immunohistochemistry (IHC) is a method utilized to detect specific proteins in tissue samples through antigen-antibody interactions using enzyme-labeled antibodies as markers. This method plays a vital role in diagnosing various diseases, such as cancer, by identifying specific biomarkers associated with tumor cells or surrounding tissues. In situ hybridization (ISH) is a technique that detects specific RNA or DNA sequences within cells in tissue samples. This method helps evaluate gene expression patterns, chromosomal abnormalities, and copy number variations. Fluorescence in situ hybridization utilizes fluorescent probes for detection. Special staining techniques visualize specific cellular components or highlight certain structures within histological samples. Digital pathology offers significant advantages in terms of efficiency, accuracy, and collaboration potential, while IHC and ISH are crucial for understanding the molecular characteristics of tissues and detecting specific biomarkers. Special staining techniques provide additional insights into cellular structures not visible through conventional methods.

Product: Proliferating use of tissue-processing systems for efficient processing and analyzing diagnosing tissue samples
Accessories are crucial in ensuring precise tissue diagnosis by complementing the function of instruments and consumables. Accessories typically refer to a wide range of supplementary products and components used with the primary tissue diagnostic instruments and equipment. These accessories enhance tissue diagnostic tools and devices' performance, efficiency, and functionality. Consumable products detect specific biomarkers essential for various steps in tissue sample preparation, staining, analysis, and storage. They are integral to the day-to-day operations of tissue diagnostic laboratories. The tissue diagnostics market encompasses various instruments and equipment for collecting, processing, analyzing, and diagnosing tissue samples. These instruments are essential for accurately assessing tissue specimens and play a crucial role in fields such as pathology, histology, and clinical diagnostics. Tissue diagnostic software solutions enable the processing, storing, and analyzing digital images obtained from scanned slides. Machine learning algorithms and artificial intelligence are utilized in diagnostics programs to facilitate remote consultations between pathologists. These advanced technologies provide more accurate and precise diagnoses, ensuring enhanced patient care and treatment outcomes.

Regional Insights:
The Americas has a significant landscape in the tissue diagnostics market owing to advanced healthcare infrastructure and extensive research funding by the key manufacturers in the development of diagnostics tests. The manufacturers in the region have observed numerous

patents issued by the FDA for innovations in tissue diagnostics technology. The EMEA region has observed a developing landscape in the tissue diagnostics market due to significant investments made by the government to support research initiatives for early diagnosis of diseases such as cancer to improve diagnostic techniques. Government standards and regulations on the safety and quality of tissue diagnostics consumables have also contributed to the market growth in the region. South Africa is a hub for innovation within the African continent, with several ongoing research initiatives focused on developing efficient diagnostic tools that cater to local disease prevalence patterns. APAC region in the market has a developing growth due to technological advancements, investment in research and development of state-of-the-art tissue diagnostic technologies, increasing cancer incidence, and government initiatives encouraging local manufacturing of diagnostic equipment, fostering innovation within the country's tissue diagnostics industry.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Tissue Diagnostics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Tissue Diagnostics Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Tissue Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam Plc, Agilent Technologies, Inc., Atlas Antibodies AB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biogenex Laboratories Inc., BioIVT, LLC, bioMérieux SA, Cardinal Health, Inc., Castle Biosciences, Inc., Cell Signaling Technology, Inc., Diagnostic BioSystems Inc., F. Hoffmann-La Roche Ltd, Leica Biosystems by Danaher Corporation, McKesson Corporation, Merck KGaA, MILESTONE MEDICAL Srl, PathAI, Inc., Pfizer Inc., PROGEN Biotechnik GmbH, QIAGEN N.V., Quest Diagnostics Incorporated, Sekisui Diagnostics, LLC, Siemens Healthineers AG, SLEE medical GmbH, and Thermo Fisher Scientific Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/tissue-

diagnostics?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Tissue Diagnostics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Accessories, Consumables, Instruments, and Software. The Consumables is further studied across Antibodies, Kits, Probes, and Reagents. The Instruments is further studied across Scanners, Slide-staining Systems, Tissue Microarrays, and Tissue-processing Systems. The Consumables commanded largest market share of 46.12% in 2022, followed by Instruments.

Based on Technology, market is studied across Digital Pathology & Workflow, Immunohistochemistry, In Situ Hybridization, and Special Staining. The Special Staining commanded largest market share of 24.23% in 2022, followed by Immunohistochemistry.

Based on Indications, market is studied across Breast Cancer, Gastric Cancer, Lymphoma, Non Small Cell Lung Cancer, and Prostate Cancer. The Lymphoma commanded largest market share of 19.42% in 2022, followed by Non Small Cell Lung Cancer.

Based on End-User, market is studied across Clinical Pathology, Contract Research Organization, Hospitals, Pharmaceutical Organizations, and Research Laboratories. The Clinical Pathology commanded largest market share of 31.91% in 2022, followed by Hospitals.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 39.68% in 2022, followed by Americas.

Key Topics Covered:

6. Tissue Diagnostics Market, by Product
7. Tissue Diagnostics Market, by Technology
8. Tissue Diagnostics Market, by Indications
9. Tissue Diagnostics Market, by End-User
10. Americas Tissue Diagnostics Market
11. Asia-Pacific Tissue Diagnostics Market
12. Europe, Middle East & Africa Tissue Diagnostics Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Tissue Diagnostics Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Tissue Diagnostics Market?
3. What is the competitive strategic window for opportunities in the Tissue Diagnostics Market?
4. What are the technology trends and regulatory frameworks in the Tissue Diagnostics Market?
5. What is the market share of the leading vendors in the Tissue Diagnostics Market?
6. What modes and strategic moves are considered suitable for entering the Tissue Diagnostics Market?

Read More @ https://www.360iresearch.com/library/intelligence/tissue-diagnostics?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+1 530-264-8485
ketan@360iresearch.com